Company intelligence / Profile preview
FullHope Biomedical Co., Ltd.
New Taipei City, Taiwanfhb.com.tw ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has multiple programs in development, with their lead candidate FHCT001 for solid tumors in Phase 1, FHCT003 for solid tumors with IND approval, and FHCT002 for autoimmune diseases in preclinical stage. They also have a Dendritic Killer Cell (DKC) therapy for Hepatocellular Carcinoma in pending status.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Immune cell therapyCAR-NKCell-based immunotherapies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Major medical centersInternational partnerships in development
Beyond the preview
Go deeper on FullHope Biomedical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FullHope Biomedical Co., Ltd..